Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: End2War who wrote (1182)	10/7/2025 5:13:07 PM
From: waitwatchwander	Respond to of 1216

---> can induce metastasis That's much different than "does". Anktiva's use earlier on in the treatment cycle is what needs to be put through trials. Why that is not happening isn't really clear but I suspect it has something to do with the length of such a trial to obtain positive outcomes. Given all treatments kill off affected cells initial cancer treatment impacts are going to be bad. I only trust better thought is occurring in this area as the sooner one starts on such a process the sooner validation of earlier Anktiva usage will be achieved.